scholarly journals AIDS-Related Kaposi Sarcoma T1 (Poor Risk): Pulmonary Involvement

2020 ◽  
Author(s):  
Keyword(s):  
Kaposi Sarcoma ◽  
Pulmonary Involvement ◽  
Poor Risk

Pulmonary Involvement of Kaposi Sarcoma in an AIDS Patient: Radiologic and Pathologic Findings

2002 ◽  
Vol 46 (1) ◽  
pp. 37 ◽  
Author(s):  
Seung Ho Kim ◽  
Jin Mo Goo ◽  
Jun Woo Lee ◽  
Myung Jin Chung ◽  
Yu Jin Lee ◽  
...  
Keyword(s):  
Kaposi Sarcoma ◽  
Pulmonary Involvement ◽  
Pathologic Findings

Presence of Human Herpesvirus 8 DNA Sequences in Renal Transplantation-Associated Pleural Kaposi Sarcoma

1999 ◽  
Vol 123 (12) ◽  
pp. 1269-1273
Author(s):  
J. Javier Gómez-Román ◽  
J. Gonzalo Ocejo-Vinyals ◽  
Pablo Sánchez-Velasco ◽  
Francisco Leyva-Cobián ◽  
J. Fernando Val-Bernal
Keyword(s):  
Kidney Transplantation ◽  
Pleural Effusion ◽  
Dna Sequences ◽  
Blot Hybridization ◽  
Human Herpesvirus ◽  
Kaposi Sarcoma ◽  
Southern Blot Hybridization ◽  
Pulmonary Involvement ◽  
Human Herpesvirus 8 ◽  
Herpesvirus 8

Abstract Objective.—To describe one case of symptomatic skin and pleural Kaposi sarcoma (KS) associated with kidney transplantation. Diagnosis was supported by morphologic study and human herpesvirus 8 (HHV-8) detection in both tissues. Pulmonary involvement was not present. Design.—The presence of HHV-8 DNA sequences was proved using polymerase chain reaction (PCR), Southern blot hybridization, and in situ hybridization. Setting.—Human herpesvirus 8 is found in most KS from patients with and without the acquired immunodeficiency syndrome. Clinically significant pulmonary infiltration by KS is diagnosed uncommonly antemortem, and pleural disease is exceptional. Patient.—A 49-year-old man who had renal transplant with immunosuppressive therapy (tacrolimus and prednisone) and developed a cutaneous KS. A pleural effusion appeared without pulmonary involvement. Both lesions disappeared when immunosuppressive drugs were suspended. Later, the pleural effusion and the cutaneous lesions reappeared. Pleural biopsy specimens showed KS infiltration. Outcome.—The patient refused treatment and was lost to follow-up. Results.—The skin and pleural biopsies showed a proliferation of spindle-shaped cells positive for CD34. The HHV-8 sequences were detected by nested PCR. No amplification was detected in uninvolved skin from the patient or in peripheral blood mononuclear cells from 10 healthy individuals used as controls. The Southern blot hybridization confirmed these results. Conclusions.—To our knowledge, this is the first report of HHV-8 in symptomatic pleural KS, which was probably associated with immunosuppression after kidney transplantation. The demonstration of HHV-8 DNA in biopsy material in the appropriate cells could be diagnostic when the morphologic setting is consistent with KS.

scholarly journals Impact of valganciclovir therapy on severe IRIS-Kaposi Sarcoma mortality: an open-label, parallel, randomized controlled trial.

2021 ◽  
Author(s):  
Patricia Volkow ◽  
Leslie Chavez-Galan ◽  
Lucero Ramon-Luing ◽  
Judith Cruz-Velazquez ◽  
Patricia Cornejo-Juarez ◽  
...  
Keyword(s):  
Controlled Trial ◽  
Kaposi Sarcoma ◽  
Pulmonary Involvement ◽  
Skin Lesions ◽  
Attributable Mortality ◽  
Control Group ◽  
Open Label ◽  
Parallel Group ◽  
Pulmonary Lymph Node ◽  
The Difference

High HHV-8 viral load (VL) in Kaposi Sarcoma (KS) has been associated with severe Immune reconstitution inflammatory syndrome (S-IRIS-KS), which can occur after initiating cART, and is linked with high mortality particularly in patients with pulmonary involvement. We investigate if valganciclovir initiated before cART decreases HHV-8 VL and assess if it reduces the incidence of S-IRIS-KS and its attributable mortality. Methods: Open-label parallel-group randomized clinical trial in AIDS cART naive patients with disseminated KS (DKS) as defined by at least two of the following: pulmonary, lymph-node or gastrointestinal involvement, lymphedema, or equal or more 30 skin lesions. In the experimental group (EG), patients were randomized to valganciclovir 900 mg BID four weeks before cART and continued until week-48; in the control group (CG), cART was initiated on week-0. Non-severe-IRIS-KS was defined as: increase in the number of lesions plus equal or more than one log10 HIV-VL decrease or equal or more than 50 cells/mm3 increase or equal or more than 2-fold rise in baseline CD4+ cells. S-IRIS-KS was defined as abrupt clinical worsening of KS lesions and/or fever after ruling out another infection following cART initiation, and at least three of the following: thrombocytopenia, anemia, hyponatremia, or hypoalbuminemia. Results: 40 patients were randomized and 37 completed the study. In the ITT analysis, the overall mortality did not differ between groups. In the per-protocol analyses, the difference showed a trend for higher S-IRIS-KS mortality in the CG 3/19 (15.7%), compared to EG 0/18 (p=0.07). The incidence of S-IRIS KS was significantly lower in the EG; two patients, one each had S-IRIS-KS episode (0.038 per 100 patient-days) compared to CG group, four patients developed 12 S-IRIS-KS episodes (0.21 per 100 patient-days); incidence rate of 0.09 (95% CI 0.02-0.5 p=0.006). Mortality in patients with pulmonary KS was significantly lower in EG, 3/4 in CG vs 0/5 in EG. S-IRIS-KS was associated with higher HHV-8-VL; IL6 and CRP; valganciclovir was protective. Of survivors at week 48, 82% achieved more than 80% remission. No difference was found between groups in the number of non-S-IRIS-KS events. Conclusions: Valganciclovir significantly reduced the episodes of S-IRIS-KS although attributable KS mortality was lower in the EG the difference was not significant (p=0.07). Mortality was significantly lower in EG patients with pulmonary KS.

scholarly journals Classic kaposi sarcoma with pulmonary involvement mimicking endobronchial tuberculosis in a child

2012 ◽  
Vol 48 (3) ◽  
pp. 310-312 ◽  
Author(s):  
Fatma B. Cakir ◽  
Erkan Cakir ◽  
Nukhet Tuzuner ◽  
Arif Kut
Keyword(s):  
Kaposi Sarcoma ◽  
Pulmonary Involvement ◽  
Endobronchial Tuberculosis ◽  
Classic Kaposi Sarcoma

Kaposi Sarcoma With Extensive Pulmonary Involvement in an Immunocompetent Host

CHEST Journal ◽  
2010 ◽  
Vol 138 (4) ◽  
pp. 125A ◽  
Author(s):  
Getinet Ayalew ◽  
Avrille George ◽  
Shella Mongia ◽  
Carmencita Yudis ◽  
Arvind J. Ponnambalam ◽  
...  
Keyword(s):  
Kaposi Sarcoma ◽  
Pulmonary Involvement ◽  
Immunocompetent Host

scholarly journals Kaposi Sarcoma in HIV Infected Patients

2016 ◽  
Vol 62 (2) ◽  
pp. 285-288
Author(s):  
Raluca Jipa ◽  
Oana Săndulescu ◽  
Eliza Manea ◽  
Şerban Benea ◽  
Otilia Benea ◽  
...  
Keyword(s):  
Tertiary Care Hospital ◽  
Tertiary Care ◽  
Kaposi Sarcoma ◽  
Stage Iv ◽  
Care Hospital ◽  
Gastrointestinal Involvement ◽  
Late Presenters ◽  
Cd4 Cell Count ◽  
Poor Risk ◽  
Cd4 Cell

AbstractObjective: The aim of the study was to describe clinical and laboratory characteristics in HIV-infected patients with Kaposi sarcoma (KS).Methods: We retrospectively studied data on HIV-infected patients hospitalized in one tertiary care hospital in Bucharest, Romania, in whom Kaposi Sarcoma was diagnosed, between January 2008 and November 2013.Results: We identified 27 HIV-infected patients diagnosed with KS within 6 years. They had a median age of 42 years old and a median CD4 cell count of 101 cells per mm3 at the time of KS diagnosis. All patients received antiretroviral therapy (ART), with 18 patients (66%) already on ART at the time of KS diagnosis. Most patients (59%) were classified as ACTG poor-risk and 56% as Mitsuyasu stage I. The overall prognosis was poor, with 41% mortality, in a median time span of 6 months, significantly correlated with gastrointestinal involvement (p=0.019), poor-risk KS in ACTG classification (p<0.001) and stage IV Mitsuyasu (p=0.006).Conclusion: KS remains an important cause of morbidity and mortality in patients with HIV infection, especially in late presenters.

Sign in / Sign up

Export Citation Format

Share Document